Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
華盛頓州溫哥華和紐約，2025年1月2日（全球新聞稿） -- Absci公司（納斯達克：ABSI），一家以數據爲驅動的生成型人工智能藥物創制公司，今日宣佈將參加即將舉行的第43屆摩根大通醫療會議，地點在加利福尼亞州舊金山。
Absci management is scheduled to present on Wednesday, January 15th at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company's investor relations website at: investors.absci.com.
Absci管理層計劃於1月15日（星期三）太平洋時間下午4:30（東部時間晚上7:30）進行演講。感興趣的各方可以通過公司的投資者關係網站訪問演講的現場直播和檔案，網址爲：investors.absci.com。
About Absci
關於Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Absci 是一家以數據爲先的生成式人工智能藥物創制公司，結合人工智能與可擴展的溼實驗室技術，以更快地爲患者創造更好的生物製品。我們的 綜合藥物創制 該平台釋放了加速臨牀時間的潛力，並通過同時優化多個對開發和治療益處都重要的藥物特性來增加成功的概率。通過數據進行訓練，利用人工智能進行創造，以及通過溼實驗室進行驗證，我們每週可以篩選數十億個電芯，使我們能夠在短短六週內從人工智能設計的候選者轉變爲溼實驗室驗證的候選者。Absci的總部位於華盛頓州溫哥華，我們的人工智能研究實驗室位於紐約市，創新中心位於瑞士楚格。請訪問 並在LinkedIn上關注我們（@absci），X（推特）（@Abscibio), 和 YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
投資者聯繫
亞歷克斯·可汗
財務副總裁及投資者關係
investors@absci.com
Media Contact
press@absci.com
媒體聯繫
press@absci.com
譯文內容由第三人軟體翻譯。
